Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone Furoate Nasal Spray in Children with Seasonal Allergic Rhinitis
NCT03879772Phase 3
Key facts
- Status
- Completed
- Start
- Mar 1996
- Primary completion
- Jul 1996
- Sponsor
- Organon & Co.
- Modality
- Small Molecules
- Conditions
- seasonal allergic rhinitis (SAR)
01
Overview
Phase 3, randomised, double-blind trial of mometasone furoate nasal spray in seasonal allergic rhinitis (SAR) (5 arms), sponsored by Organon & Co. Primary endpoint: Total Nasal Symptom Score at Day 8. Started Mar 1996; status: completed.
02
Design
5 arms- Study design
- RandomizedDouble-blind
MFNS 25 mcg QD
Mometasone furoate 25 mcg QD
MFNS 100 mcg QD
Mometasone furoate 100 mcg QD
MFNS 200 mcg QD
Mometasone furoate 200 mcg QD
BDP 84 mcg BID
Beclomethasone dipropionate 84 mcg BID
Placebo
Placebo nasal spray
03
Who it enrols
Children 6-11 with seasonal allergic rhinitis history >1 year and positive skin test. Excludes asthma requiring steroids, sinusitis, structural abnormalities, and recent infections.
04
Endpoints
Primary
Total Nasal Symptom Score
Secondary
Total Nasal Symptom Score
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT03879772.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879772.